EXEL — Exelixis, Inc.
4 mentions in the last 24 hours · 0.02% of all mentions
Why people talked about EXEL (2026-10-30)
- Exelixis reported Q3 2026 financial results, with revenue increasing by 10% to $658.7 million.
- The FDA extended the PDUFA date for zanzalintinib in colorectal cancer to March 3, 2027.
- Generic competition for Cabometyx is not expected until late 2029 or 2030.
| GDELT | 2 | news |
| RSS Bundle | 2 | news |
| Bluesky | 0 | community |
| SEC EDGAR 8-K | 0 | filings |
| YouTube | 0 | community |